Article

Segment 6: Learning About CancerLinQ as It Rolls Out

Daniel Hayes, MD, explains the implementation of the American Society of Clinical Oncology's CancerLinQ for beta testing.

Moderator Surabhi Dangi-Garimella asked Daniel Hayes, MD, who has been elected president of the American Society of Clinical Oncology (ASCO) for the term beginning in June 2016, what changes practices would have to adopt to implement ASCO’s CancerLinQ.

Currently, ASCO is rolling out CancerLinQ for beta testing in a number of practices, but he admits they don’t really know how it will function until they put it to work.

“I think as it becomes increasingly more successful, other practices will see the advantages of being enrolled,” he said.

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Videos
Constance Blunt, MD, medical oncologist, Mary Bird Perkins Cancer Center
Coral Omene, MD, PhD, sitting for a vieo interview
David Awad, PharmD, BCOP
Screenshot of Coral Omene, MD, PhD
ASCO 2025
Constance Blunt, MD, medical oncologist, Mary Bird Perkins Cancer Center
Cathy Eng, MD, FACP, FASCO
Nini Wu, MD, Navista
Eileen Peng, PharmD, sitting for a video interview
Nini Wu, MD, Navista
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo